Botox For Migraine: How Will The Market Size Up?

The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.